Supernus Pharma to acquire Sage Therapeutics in up to $795 million deal
June 16 (Reuters) - Drugmaker Supernus Pharmaceuticals SUPN.O said on Monday it will acquire Sage Therapeutics SAGE.O, which makes treatments for neurological conditions, in a deal worth up to $795 million. Supernus has offered $8.50 in cash for each of Sage's share and up to $3.50 per share in cash if certain milestones are achieved. Shares of Sage Therapeutics were halted in premarket trading. (Reporting by Bhanvi Satija and Puyaan Singh in Bengaluru; Editing by Shinjini Ganguli) ((Bhanvi.Satija@thomsonreuters.com; Outside U.S. +91 9873062788;))
Recent news on Supernus Pharmaceuticals
See all newsHuron Consulting poised to hit fresh record ahead of S&P SmallCap addition
Brief: S&P Dow Jones Indices Msg Rangers And Huron Consulting Group Set To Join S&P Smallcap 600
Brief: Supernus Pharmaceuticals Says FDA Grants Seven Years Orphan-Drug Exclusivity For Onapgo
Supernus Pharmaceuticals Inc reports results for the quarter ended June 30 - Earnings Summary
U.S. STOCKS ON THE MOVE -Micron Technology, Ares Management, Boeing